Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA

Trieu, Judy A.; Bilal, Mohammad; Saraireh, Hamzeh; Wang, Andrew Y.

doi:10.1007/s10620-019-05526-5

Cited by 21 publications

(23 citation statements)

References 79 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Even though the role of extension, localisation, or phenotype of premalignant lesions on GC risk is still a matter of debate, risk stratification and surveillance are nowadays unanimously accepted in order to decrease the burden of mortality[130,131]. At the same time, there are significant differences in the risk of progression to cancer in various populations.…”

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori and cytokine gene variants as predictors of premalignant gastric lesions

Negovan¹,

Iancu²,

Fülöp³

et al. 2019

WJG

View full text Add to dashboard Cite

Gastric cancer remains the third leading cause of mortality from cancer worldwide and carries a poor prognosis, due largely to late diagnosis. The importance of the interaction between Helicobacter pylori ( H. pylori ) infection, the main risk factor, and host-related genetic factors has been studied intensively in recent years. The genetic predisposition for non-hereditary gastric cancer is difficult to assess, as neither the real prevalence of premalignant gastric lesions in various populations nor the environmental risk factors for cancer progression are clearly defined. For non-cardiac intestinal-type cancer, identifying the factors that modulate the progression from inflammation toward cancer is crucial in order to develop preventive strategies. The role of cytokines and their gene variants has been questioned in regard to non-self-limiting H. pylori gastritis and its evolution to gastric atrophy and intestinal metaplasia; the literature now includes various and non-conclusive results on this topic. The influence of the majority of cytokine single nucleotide polymorphisms has been investigated for gastric cancer but not for preneoplastic gastric lesions. Among the investigated gene variants onlyIL10T-819C, IL-8-251, IL-18RAP917997, IL-22 rs1179251, IL1-B-511, IL1-B-3954, IL4R-398 and IL1RN were identified as predictors for premalignant gastric lesions risk. One of the most important limiting factors is the inhomogeneity of the studies ( e.g ., the lack of data on concomitant H. pylori infection, methods used to assess preneoplastic lesions, and source population). Testing the modifying effect of H. pylori infection upon the relationship between cytokine gene variants and premalignant gastric lesions, or even testing the interaction between H. pylori and cytokine gene variants in multivariable models adjusted for potential covariates, could increase generalizability of results.

show abstract

Section: Resultsmentioning

confidence: 99%

Helicobacter pylori and cytokine gene variants as predictors of premalignant gastric lesions

Negovan¹,

Iancu²,

Fülöp³

et al. 2019

WJG

View full text Add to dashboard Cite

show abstract

“…Следует заметить, что в американских обзорах по ведению пациентов с метаплазией в желудке разрешается выполнять морфологическое исследование не только по системе OLGA, но и по модифицированной Сиднейской системе [9,10,30].…”

Section: ведение пациентов с предраковыми изменениями в желудкеunclassified

“…Все современные международные рекомендации, включая Киотский консенсус [5], Маастрихт V [6], MAPS II [7], рекомендации Британской гастроэнтерологической ассоциации [8], работы по ведению пациентов с предраковыми изменениями в желудка в США [9,10], Японии [11] и России [31], утверждают, что эрадикация H. pylori снижает риск рака желудка, то есть представляет собой метод первичной профилактики этой патологии.…”

Section: профилактика рака желудкаunclassified

“…изменений в желудке [4]. В связи с этим в последние годы появился целый ряд международных консенсусов по ведению пациентов с атрофическим гастритом и метаплазией, среди которых следует выделить Киотский консенсус [5], Маастрихт V [6], Management of epithelial precancerous conditions and lesions in the stomach II (MAPS II) [7], рекомендации Британской гастроэнтерологической ассоциации [8] и современные обзоры по ведению пациентов с метаплазией желудка в США [9,10]. Следует также отметить традиционно высокую активность японских исследо вателей [11].…”

unclassified

See 1 more Smart Citation

Modern Aspects of Stomach Cancer Prevention

Цуканов¹,

Scientific²,

Vasyutin³

et al. 2020

View full text Add to dashboard Cite

Objective of the Review: to analyse available data on stomach cancer prevention. Key Points. Key risk factors for stomach cancer are male gender, age of >50 years old, Helicobacter pylori and smoking. A number of international consensus opinions regulate screening, diagnostics and treatment of precancer changes in stomach; it is assumed to reduce the incidence of this disease. H. pylori eradication is the key method of primary stomach cancer prevention. Modern studies demonstrate that the optimal method of H. pylori eradication is the therapy with bismuth medication, proton pump inhibitor, amoxycillin and clarithromycin for 10–14 days. Conclusion. The most efficient method of stomach cancer prevention is H. pylori eradication, smoking cessation, diet with plenty of vegetables and fruit. Secondary prevention is optimisation of diagnostics, follow-up and treatment of precancer stomach conditions. Keywords: stomach cancer, gastratrophia, Helicobacter pylori, prevention.

show abstract

“…Among the several factors that have been considered playing a role in gastric carcinogenesis, Helicobacter pylori (HP) infection is currently the most important risk factor for AG, IM, and gastric cancer [2,17,20]. Epidemiological studies suggest that HP strains containing the cagA gene are more virulent and its prevalence varies according to ethnicity and geographical location [2,[19][20][21][22]. Therefore, eradication of HP infection is regarded as a primary chemoprevention strategy for reducing the incidence of gastric cancer.…”

Section: Premalignant Conditions and Gastric Cancermentioning

confidence: 99%

Esophagogastric premalignant conditions. A literature review

Troian

Nagliati²,

Balani

2020

Journal of Gastric Surgery

View full text Add to dashboard Cite

Esophagogastric cancers are serious malignancies with high mortality and low overall survival for advanced tumors. Detection of premalignant lesions and early treatment of malignant lesions are of paramount importance. Precancerous esophagogastric conditions develop from interaction between environmental and genetic factors. Chronic irritation and inflammation may result in metaplasia, increased mutations, cellular atypia, and altered function (dysplasia). Helicobacter pylori (HP) infection is one of the most important risk factors for gastric carcinogenesis, but other environmental factors (e.g. alcohol, tobacco, nitrites, infection) and autoimmune disorders play a role as well. Esophageal adenocarcinoma (EAC) usually arises in the distal esophagus and is linked to obesity, gastroesophageal reflux disease (GERD) and Barrett’s esophagus (BE). Squamous cell carcinoma (ESCC) typically occurs in the presence of risk factors causing chronic inflammation (e.g. tobacco, alcohol abuse, achalasia, tylosis). Highquality endoscopic imaging is of primary importance in the diagnosis and assessment of premalignant and early malignant esophagogastric lesions. Biological markers such as aberrant p53 protein expression may be associated with increased risk of malignant transformation of precancerous lesions; however, none of those biomarkers has been validated for either diagnosis or risk stratification yet.

show abstract

Update on the Diagnosis and Management of Gastric Intestinal Metaplasia in the USA

Cited by 21 publications

References 79 publications

Helicobacter pylori and cytokine gene variants as predictors of premalignant gastric lesions

Helicobacter pylori and cytokine gene variants as predictors of premalignant gastric lesions

Modern Aspects of Stomach Cancer Prevention

Esophagogastric premalignant conditions. A literature review

Contact Info

Product

Resources

About